<DOC>
	<DOCNO>NCT01220648</DOCNO>
	<brief_summary>This study assess maximum tolerate dose low dose interferon conjunction nilotinib pretreated Philadelphia chromosome positive ( Ph+ ) chronic myeloid leukemia patient chronic phase ( CML-CP ) .</brief_summary>
	<brief_title>Determining Maximum Tolerated Dose Low Dose Interferon-alpha Conjunction With Nilotinib Pretreated Philadelphia Chromosome Positive ( Ph+ ) Chronic Myeloid Leukemia Patients Chronic Phase ( CML-CP )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Patients chronic myeloid leukemia chronic phase ( CMLCP ) screen Initial diagnosis CML cytogenetically confirm presence Ph+ metaphases bone marrow Patients treat nilotinib minimum 6 month ( 1 month represent 28 day ) switch previous CML treatment Patients treat stable dose 2x400mg nilotinib within last month start study treatment No grade 34 CTC toxicity nilotinib alone last month precede start study regimen Patients consider Ph confirm cytogenetic diagnosis ( 9 ; 22 ) translocation bone marrow metaphases Evidence point mutation within BCRABL gene lead clinically relevant amino acid exchange kinase domain position T315 ( gatekeeper mutation T315I ) Impaired cardiac function Severe uncontrolled medical condition ( i.e . uncontrolled diabetes , active uncontrolled infection ) . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Chronic myeloid leukemia</keyword>
	<keyword>interferon alfa</keyword>
	<keyword>nilotinib</keyword>
	<keyword>combination</keyword>
	<keyword>CML</keyword>
	<keyword>Philadelphia chromosome positive ( Ph+ ) chronic myeloid leukemia patient chronic phase ( CML-CP ) switch previous CML treatment</keyword>
</DOC>